[1] Aslan A T, Balaban H Y. Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol, 2020, 26(37): 5543-5560.
[2] Pischke S, Wedemeyer H. Hepatitis E virus infection: multiple faces of an underestimated problem. J Hepatol, 2013, 58(5): 1045-1046.
[3] Dalton H R, Kamar N, Van Eijk J J, et al. Hepatitis E virus and neurological injury. Nat Rev Neurol, 2016, 12(2): 77-85.
[4] Kamar N, Bendall R P, Peron J M, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis, 2011, 17(2): 173-179.
[5] Liu H, Ma Y. Hepatitis E virus-associated Guillain-Barre syndrome: revision of the literature. Brain Behav, 2020, 10(1): e01496.
[6] Maurissen I, Jeurissen A, Strauven T, et al. First case of anti-ganglioside GM1-positive Guillain-Barre syndrome due to hepatitis E virus infection. Infection, 2012, 40(3): 323-326.
[7] 程晓娟, 赵玉武. 双重滤过血浆置换治疗吉兰-巴雷综合征的疗效分析. 中国神经免疫学和神经病学杂志, 2022, 29(3): 226-229.
[8] Yamagishi Y, Kusunoki S. The prognosis and prognostic factor of Guillain-Barre syndrome. Rinsho Shinkeigaku, 2020, 60(4): 247-252.
[9] 黄莹, 罗翰, 徐铅辉, 等. 抗GM1抗体在格林-巴利综合征患者中的表达及与预后的关系研究. 当代医学, 2020, 26(21): 160-162. |
